A unique product development partnership seeks to address the need for new therapeutics for Chagas disease by developing and testing vaccine candidate antigens that would eventually comprise a ...

The studies described above provide a strong preclinical foundation for accelerating the development of a therapeutic human vaccine for Chagas disease. The authors are currently working to produce ...

Main Goal: The overall goal of the project is to advance the first therapeutic Chagas disease vaccine prototype through a First-in-Human Phase 1 clinical trial. SARS-CoV Vaccine Development Main Goal: ...

The General Directorate of Epidemiology reported low incidences of dengue, cholera, and leptospirosis, as can be seen in ...

Trypanosomes are parasites that cause sleeping sickness, Chagas disease, and various animal diseases. Diagnosis and treatment remain complex and no effective vaccine has been developed.

COPENHAGEN, Denmark, February 14, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Food and Drug Administration (FDA) has approved VIMKUNYA™ (Chikungunya Vaccine, Recombinant) for ...

We also have a new Chagas disease vaccine entering a Phase 1 trial, and we used that same approach to make two low-cost COVID-19 vaccines. The health economists we collaborate with said all our ...

Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, finds its roots in the intricate web of transmission ...

The advantages of a therapeutic Chagas disease vaccine compared with benznidazole alone (the current major competing product in clinical use) could include the following: Three recent ...

Trypanosomes are parasites that cause sleeping sickness, Chagas disease, and various animal diseases. Diagnosis and treatment remain complex and no effective vaccine has been developed. A better ...